GSK Share Price Performance
UK£18.25
5.05 (38.27%)
0.1% undervalued intrinsic discount
UK£18.27
Fair Value
Price UK£18.25
AnalystConsensusTarget UK£18.27
AnalystHighTarget UK£25.15
AnalystLowTarget UK£11.20
Fair ValueUK£18.64
Share Pricen/a
- 4 Narratives written by author
- 2 Comments on narratives written by author
- 409 Fair Values set on narratives written by author
GSK Community Narratives
AN
Fair Value UK£18.64 2.1% undervalued intrinsic discount
GSK: Technology Adoption And U.S. Investment Will Shape Sector Positioning Amid Policy Shifts
2users have liked this narrative
2users have commented on this narrative
172users have followed this narrative
AN
Fair Value UK£23.63 22.8% undervalued intrinsic discount
Digital Transformation And Global Demographics Will Fuel Expansion
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value UK£11.2 62.9% overvalued intrinsic discount
Cost Controls In The US And Europe Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
GSK: March Madness Lineup
March Madness is here, or so they say on the basketball courts. But Marchs madness is slowly moving off to more than just the courts.Read more
2users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
DA
UK£78
76.6% undervalued intrinsic discount
DailyInvestors's Fair Value
Revenue
49.03% p.a.
Profit Margin
8.21%
Future PE
23.02x
Price in 2029
UK£103.62
GSK: Technology Adoption And U.S. Investment Will Shape Sector Positioning Amid Policy Shifts
Key Takeaways Robust growth in vaccines and specialty medicines, alongside innovation in oncology and immunology, positions GSK for sustained revenue and margin expansion. Diversification, operational efficiencies, and accelerated R&D enhance resilience, supporting strong long-term sales and earnings potential despite industry pressures.Read more
2users have liked this narrative
2users have commented on this narrative
172users have followed this narrative
AN
UK£18.64
2.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
4.58% p.a.
Profit Margin
19.71%
Future PE
12.19x
Price in 2028
UK£22.87
Digital Transformation And Global Demographics Will Fuel Expansion
Key Takeaways Accelerated advancement in specialty medicines, vaccines, and anti-infective therapies positions GSK for outsized revenue and margin growth relative to peers. Strategic investments in digital capabilities and global scale enhance productivity, unlock new markets, and support long-term, defensible earnings streams.Read more
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
UK£23.63
22.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
8.52% p.a.
Profit Margin
19.81%
Future PE
14.04x
Price in 2028
UK£28.46
Cost Controls In The US And Europe Will Squeeze Margins
Key Takeaways Escalating pricing pressures and patent expirations threaten growth, margins, and the value from new and existing products across key markets. Weak R&D productivity, mounting legal risks, and emerging market volatility undermine earnings stability and long-term strategic goals.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
UK£11.2
62.9% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
3.06% p.a.
Profit Margin
19.15%
Future PE
8.03x
Price in 2028
UK£13.49
Trending Discussion
Recently Updated Narratives
DA
GSK: March Madness Lineup
Fair Value: UK£78 76.6% undervalued intrinsic discount
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GSK: Vaccine Strength And Manufacturing Investments Will Drive Balanced Returns Amid Policy Uncertainty
Fair Value: UK£18.64 2.1% undervalued intrinsic discount
172 followersusers have followed this narrative
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Cost Controls In The US And Europe Will Squeeze Margins
Fair Value: UK£11.2 62.9% overvalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GSK plc Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 1.37
- 72.43%
- 17.08%
- 112.7%
About GSK
- Founded
- 1715
- Employees
- 68629
- CEO
- WebsiteView website
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
